The global clean label mold inhibitors market size accounted for USD 1.14 billion in 2024, grew to USD 1.22 billion in 2025 and is projected to surpass around USD 2.24 billion by 2034, representing a CAGR of 6.93% between 2024 and 2034. The North America clean label mold inhibitors market size is calculated at USD 440 million in 2024 and is expected to grow at a CAGR of 6.96% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clean Label Mold Inhibitors Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clean Label Mold Inhibitors Market Revenue and Volume, By Ingredient, 2024-2034
8.1.1 Stretch
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Vinegar
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Fermented Flour
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Whey
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Clean Label Mold Inhibitors Market Revenue and Volume, By End-use, 2024-2034
9.1.1. Food and Beverages
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Animal Feed
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Pharmaceuticals
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Personal Care and Cosmetics
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.1.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.2.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.3.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.4.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.5.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Ingredient (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, By End-use (2021-2034)
11.1. Kemin Industries Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Corbion
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Ara Partners
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. BioVeritas
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Ribus, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Lesaffre Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Puratos Group
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Kerry Group plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Cargill
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Tate & Lyle PLC
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample